YOLFTbeta
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

688505 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

6.86CNY-0.21 (-2.97%)

Price History

Full chart

Market Stats

Previous Close7.07
Open7.06
Day Range6.84 – 7.09
52-Week Range6.58 – 9.50
Volume5.27M
Market Cap8.92B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.12
Dividend Yield0.00%
Beta0.09
50-Day Avg8.02
200-Day Avg7.99

About

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Company Details

Leadership

  • Mr. Da Jun ZhaoCo-Founder & Executive Chairman · b. 1970
  • Ms. Xue Yan ACCA, CIA, CICPA, FCCA, HKICPABoard Secretary, CFO, GM & Executive Director · b. 1982
  • Ms. Dai Qing YuDeputy General Manager · b. 1973
  • Mr. Yu ChenDeputy General Manager · b. 1974
  • Wen ZhangAccounting Supervisor
  • Mr. Luo Chun WangCore Technical Personnel · b. 1970
  • Mr. Jian Ping JiangCore Technical Personnel · b. 1970
  • Mr. Wen Bo ZhangCore Technical Personnel · b. 1967
  • Ms. Ji Ning TaoCore Technical Personnel · b. 1972

Financials

Income Statement

Currency: CNY2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue10.57M20.12M19.76M24.93M31.99M61.91M92.39M133.89M232.53M415.93M470.90M579.46M621.87M497.69M741.84M1.03B833.80M1.14B1.03B850.73M709.40M685.80M
Growth (%)-+90.38%-1.75%+26.12%+28.33%+93.51%+49.24%+44.92%+73.67%+78.87%+13.22%+23.05%+7.32%-19.97%+49.06%+38.75%-18.99%+36.76%-9.57%-17.50%-16.61%-3.33%
Cost of Revenue10.42M12.09M9.41M10.88M12.21M16.18M18.70M23.03M23.56M32.41M36.82M50.01M46.51M54.79M71.45M77.15M66.09M81.02M86.29M74.08M63.46M69.31M
Gross Profit150.00K8.02M10.35M14.05M19.78M45.72M73.69M110.86M208.97M383.52M434.08M529.45M575.36M442.90M670.39M952.14M767.72M1.06B944.87M776.66M645.95M685.80M
Gross Margin1.42%39.89%52.37%56.35%61.83%73.86%79.76%82.80%89.87%92.21%92.18%91.37%92.52%88.99%90.37%92.50%92.07%92.89%91.63%91.29%91.05%100.00%
Operating Expense31.18M39.78M31.66M40.80M41.43M50.77M66.76M68.37M142.42M275.16M304.12M376.39M420.24M366.90M577.37M704.66M594.69M841.91M811.60M679.57M643.55M841.20M
Operating Income-31.03M-31.76M-21.31M-26.75M-21.65M-5.05M6.93M42.49M66.55M108.36M129.96M153.06M155.12M76.00M93.02M247.48M173.03M217.38M133.27M97.09M2.39M-155.40M
Operating Margin-293.69%-157.86%-107.82%-107.32%-67.67%-8.16%7.50%31.73%28.62%26.05%27.60%26.41%24.94%15.27%12.54%24.04%20.75%19.06%12.92%11.41%0.34%-22.66%
EBITDA-17.03M-31.76M-14.91M-20.83M-15.48M2.19M14.66M49.31M73.55M119.12M153.57M180.59M184.22M118.39M150.35M303.99M231.54M270.89M206.81M152.61M59.61M-102.36M
EBITDA Margin-161.19%-157.86%-75.45%-83.56%-48.38%3.54%15.86%36.83%31.63%28.64%32.61%31.16%29.62%23.79%20.27%29.53%27.77%23.76%20.06%17.94%8.40%-14.93%
Net Income-24.90M-30.36M-22.03M-29.55M-23.40M-7.32M3.68M30.83M53.16M87.22M118.26M127.72M138.71M75.29M112.13M227.36M164.66M213.30M138.00M108.63M39.73M-157.44M
Net Income Margin-235.65%-150.90%-111.47%-118.55%-73.15%-11.82%3.98%23.02%22.86%20.97%25.11%22.04%22.30%15.13%15.11%22.09%19.75%18.71%13.38%12.77%5.60%-22.96%
R&D16.54M24.44M15.57M15.86M16.00M22.11M23.82M32.89M46.30M69.07M106.21M110.79M95.78M118.29M119.18M127.82M139.27M224.39M226.85M243.76M325.79M358.00M
R&D as % of Total Revenue156.54%121.48%78.78%63.64%50.03%35.71%25.78%24.57%19.91%16.61%22.55%19.12%15.40%23.77%16.06%12.42%16.70%19.68%22.00%28.65%45.92%52.20%
Interest Expense--712.00K1.25M1.48M2.54M2.95M4.86M6.17M5.44M1.87M7.13M4.06M6.08M6.71M6.59M5.96M1.19M1.68M3.19M664.32K662.89K
Interest Expense % of Total Revenue--3.60%5.02%4.64%4.11%3.19%3.63%2.65%1.31%0.40%1.23%0.65%1.22%0.90%0.64%0.71%0.10%0.16%0.37%0.09%0.10%

Balance Sheet

Currency: CNY2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets142.91M145.02M130.38M158.45M298.83M304.15M358.88M537.30M749.22M824.48M1.02B1.12B1.15B1.46B1.56B2.50B2.78B2.98B2.88B2.59B2.39B
Total Liabilities19.18M43.32M59.34M82.57M130.46M135.45M157.81M277.18M183.29M148.06M254.43M247.70M252.65M466.08M631.68M492.21M591.58M722.99M518.12M281.23M273.93M
Total Equity120.56M99.61M70.06M73.59M135.69M139.24M170.06M223.23M532.72M650.98M732.63M843.55M872.39M982.07M931.53M2.01B2.19B2.26B2.36B2.30B2.12B
Cash49.76M44.18M26.28M49.35M86.90M90.31M110.07M158.27M324.93M356.10M446.00M511.28M468.14M588.22M576.80M1.40B1.21B1.29B1.20B1.06B1.15B
Total Debt-20.00M42.65M52.65M64.65M72.98M78.31M126.50M40.00M25.00M125.00M120.00M140.00M150.00M155.10M19.69M31.26M124.81M17.28M20.53M-
Net Debt-49.76M-24.18M16.37M3.30M-22.25M-17.32M-31.76M-31.77M-284.93M-331.10M-321.00M-391.28M-328.14M-438.22M-421.70M-1.38B-1.18B-1.16B-1.18B-1.04B-

Cash Flow

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-21.40M-17.18M-15.89M7.72M-7.11M49.59M110.19M89.44M88.36M96.30M140.57M42.71M173.94M269.23M113.00M268.90M165.27M71.02M-14.77M141.40M
Investing Cash Flow-14.71M-10.59M-982.00K-50.99M2.19M-35.16M-114.93M-58.55M-42.19M-61.87M-47.20M-64.56M-48.63M-21.14M-46.54M-355.67M-96.75M-45.38M-23.88M-
Financing Cash Flow31.00M10.00M40.00M80.82M8.33M5.33M52.94M135.77M-15.00M55.48M-28.00M-20.98M-5.40M-259.57M753.85M-101.16M11.61M-118.98M-101.27M-
Capital Expenditure16.86M6.28M2.92M55.82M9.41M32.99M114.69M57.38M44.91M39.75M46.82M60.94M37.79M40.39M42.41M120.12M87.30M98.97M42.67M32.37M
Free Cash Flow-38.26M-23.46M-18.81M-48.09M-16.51M16.60M-4.51M32.07M43.45M56.55M93.75M-18.23M136.15M228.85M70.59M148.78M77.96M-27.95M-57.44M109.03M
Dividends Paid-------3.69M-45.85M27.99M46.15M27.69M64.61M64.61M52.15M72.03M76.15M93.29M31.10M
FCF to OCF178.81%136.51%118.35%-622.63%232.33%33.48%-4.09%35.85%49.18%58.72%66.69%-42.68%78.27%85.00%62.47%55.33%47.17%-39.36%388.88%77.11%
Dividend Paid to FCF-------11.51%-81.09%29.85%-253.15%20.34%28.23%91.53%35.05%92.39%-272.44%-162.42%28.52%

Earnings

Report DateJun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Mar 25, 2022Apr 29, 2022Aug 25, 2022Oct 27, 2022Mar 27, 2023Apr 28, 2023Aug 10, 2023
EPS Estimate-------------
EPS Actual0.050.050.080.000.060.050.090.00-0.040.070.100.010.06
Surprise-------------
Timing------Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap8.92B
Enterprise Value5.58B
Trailing P/E0.00
Forward P/E0.00
Price / Sales13.35
Price / Book4.15
EPS-0.12
Book Value2.08
Revenue (TTM)667.94M
Gross Profit (TTM)605.89M
EBITDA-84.86M
Profit Margin-18.90%
Operating Margin8.86%
Return on Equity-5.71%
Return on Assets-3.37%
Shares Outstanding703.00M
Shares Float437.20M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio234.79%

Dividends

20251×
0.03Jul 18, 2025
20242×
0.02Aug 30, 20240.07Jul 12, 2024
20231×
0.07Jul 7, 2023
20221×
0.07Jul 20, 2022
20211×
0.05Jun 23, 2021